A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer

Clinical trial NCT04467515 · TERMINATED

Trial details

NCT number: NCT04467515
Sponsor: Precirix
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment

Start date: 2021-09-14
Primary completion: 2023-12-11
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.